# Antimicrobial and Biocompatible Endotracheal Tubes

> **NIH NIH R44** · WYNNVISION, LLC · 2020 · $786,197

## Abstract

Ventilator-associated pneumonia (VAP) occurs 48–72 hours (or more) following
endotracheal intubation and accounts for half of all cases of hospital-acquired
pneumonia. CDC reports and many clinical studies point to a critical need for
preventing ventilator associated infections rather than fighting an often losing battle
against acquired infection. Responding to this unmet need, WynnVision LLC, “WV” will
leverage strong preliminary results for antimicrobial-but-cytocompatible (ABC) nano-
overcoats on as-manufactured intubation products to develop a new technology for
eliminating or greatly reducing VAP/VAE. The WV approach, protected by a recent
patent application, will involve multidisciplinary activities and third party testing to
facilitate approaching FDA for approval.

## Key facts

- **NIH application ID:** 9931267
- **Project number:** 5R44HL142391-03
- **Recipient organization:** WYNNVISION, LLC
- **Principal Investigator:** XUEJUN WEN
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $786,197
- **Award type:** 5
- **Project period:** 2018-08-15 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9931267

## Citation

> US National Institutes of Health, RePORTER application 9931267, Antimicrobial and Biocompatible Endotracheal Tubes (5R44HL142391-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9931267. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*